Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aridis Pharmaceuticals (ARDS : NSDQ)
 
 • Company Description   
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company's product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States.

Number of Employees: 34

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.07 Daily Weekly Monthly
20 Day Moving Average: 59,348 shares
Shares Outstanding: 17.70 (millions)
Market Capitalization: $18.94 (millions)
Beta: 0.42
52 Week High: $7.72
52 Week Low: $0.88
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.74% -10.74%
12 Week -50.69% -45.80%
Year To Date -54.08% -46.51%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
983 University Avenue Bldg. B
-
Los Gatos,CA 95032
USA
ph: 408-385-1742
fax: 408-960-3822
dave@redchip.com http://www.aridispharma.com
 
 • General Corporate Information   
Officers
Vu Truong - Chief Executive Officer; Chief Scientific Officer
Eric Patzer - Executive Chairman and Director
Fred Kurland - Chief Financial Officer and Principal Accounting O
Robert R. Ruffolo - Director
John Hamilton - Director

Peer Information
Aridis Pharmaceuticals (CORR.)
Aridis Pharmaceuticals (RSPI)
Aridis Pharmaceuticals (CGXP)
Aridis Pharmaceuticals (BGEN)
Aridis Pharmaceuticals (GTBP)
Aridis Pharmaceuticals (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 040334104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 17.70
Most Recent Split Date: (:1)
Beta: 0.42
Market Capitalization: $18.94 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.47 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.77 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 8.22
EPS Growth
vs. Year Ago Period: 42.86%
vs. Previous Quarter: 52.17%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 108.25%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -219.55
12/31/21 - -232.04
09/30/21 - -227.65
Current Ratio
03/31/22 - 0.64
12/31/21 - 0.73
09/30/21 - 0.82
Quick Ratio
03/31/22 - -
12/31/21 - 0.73
09/30/21 - 0.82
Operating Margin
03/31/22 - -2,097.53
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -2,066.20
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -1,868.46
12/31/21 - -2,748.73
09/30/21 - -7,154.38
Book Value
03/31/22 - -1.15
12/31/21 - -0.93
09/30/21 - -0.34
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©